Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study NB32 (32 mg naltrexone SR + 360 mg bupropion SR) significantly reduced depressive symptoms and promoted weight loss in overweight and obese women with MDD over 24 weeks, with 95% showing clinical improvement and 70% achieving remission, while maintaining a safety profile consistent with its components
The mechanisms behind this are not fully understood
Symptoms such as pain during urination, cloudy urine, or a persistent urge to urinate might indicate these issues and should not be overlooked
The STEP UP Phase 3b clinical trial, published in The Lancet Diabetes and Endocrinology in 2025, enrolled over 1,400 adults with obesity and without diabetes
Vous y trouverez toutes les rponses vos questions
Tirzepatide has a 5-day half-life, meaning significant drug remains in your system when the next dose is due
